Christopher Li and Wendy Law, both of Fred Hutchinson Cancer Research Center, have a message for leaders of DEI programs in oncology.
Soon after starting work on a book about the role the NCI-designated cancer centers have played in the National Cancer Program, Skip Trump and Eric Rosenthal got in touch with John W. Yarbro.
The University of Virginia has taken a long, circuitous path to NCI comprehensive cancer center designation, but it got there.
The National Coalition for Cancer Survivorship began in 1986 with 23 people at a hotel in Albuquerque and a $100 contribution from Patricia A. Ganz, who recalls thinking: “I don’t think I’ve ever invested in anything that was so good.”
There’s a cultural perception in drug development that enrolling a diverse, heterogeneous patient cohort can be “risky” for detecting drug effects—a perception that needs to go away, said Lola Fashoyin-Aje, associate director of the Science & Policy Program to Address Disparities at the FDA’s Oncology Center of Excellence and a deputy division director in the agency’s Office of Oncologic Diseases.
Drug manufacturers and researchers have a moral obligation to design clinical trials that adequately represent the target population for the investigational agent—and these medical products need to be safe and effective for everyone, leading clinical trial experts in oncology say.
Eric P. Winer will begin his job as director of Yale Cancer Center and physician-in-chief of Smilow Cancer Hospital at Yale on Feb. 1, but he has started his “listening tour” early.
The pandemic has accelerated the development of mRNA vaccines, which could have significant implications for cancer research, said Danny Milner, chief medical officer of the American Society for Clinical Pathology, and adjunct associate professor of immunology and infectious diseases in the Department of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health.
The Cancer Prevention and Research Institute of Texas will focus on finding solutions for health disparities among patients with cancer, Michelle Le Beau, the institute’s new chief scientific officer, said to The Cancer Letter.
When Susan Love joked that a group of breast cancer advocates in Salt Lake City should march topless to George H. W. Bush’s White House, she didn’t expect to be taken seriously.
